iRadimed Q2 2021 revenue $9.8M, GAAP EPS $0.12; guides FY21 rev $40.0-40.4M

IRADIMED CORP

2021-Q2 EPS reported $0.23 revenue$19,034,419

Q2 2021 revenue $9.8M, up 44% YoY from $6.8M; net income $1.5M vs net loss of $2.1M.
GAAP diluted EPS $0.12; non-GAAP diluted EPS $0.14, up from $0.05 in Q2 2020.
Q3 2021 guidance: rev $10.3-10.5M, GAAP EPS $0.14-0.15, non-GAAP EPS $0.16-0.17.
Full-year 2021 guidance: rev $40.0-40.4M, GAAP EPS $0.53-0.55, non-GAAP EPS $0.60-0.62.
Cash and investments $56.1M at quarter-end; operating cash flow $4.5M YTD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.